High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

NCT06394674 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
84
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Changhai Hospital

Collaborators